Fig. S1. Increased IFN-γ/IL-13 ratio in PSO and PSA patients with systemic lupus erythematosus (SLE). Three patients with SLE and four patients with PSO+PSA without SLE (P4, P6, P7, P8) and 15 treatment courses of biologics were as follow: adalimumab, 6; etanercept, 1; golimumab, 1; ustekinumab, 3; secukinumab, 3; and guselkumab, 1. The ratio of IFN-γ/IL13 was significantly increased in the SLE group ($p = 0.02$).